5-fluorouracil,Leucovorin,Oxaliplatin,Nab-paclitaxel,Gemcitabine
Ipsen
[]
 napoli-3: updated os data for nalirifox vs gem+nabp in 1st line #pdac #asco23 phs-iii, 770 pts mos 11.1 vs 9.2 mo, consistent benefit in subgroups mpfs 7.4 versus 5.6 mo, 50% subs. orr 41 vs 33%, mdor 7.3 vs 5.0 practice changing for fit pts? 
Physician-scientist, focused on translational research in hepatobiliary cancer and precision oncology